Athira Pharma Inc (NAS:ATHA)

$ 0.5499 0.0114 (2.12%) Market Cap: 21.26 Mil Enterprise Value: -46.72 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 36/100

Athira Pharma Inc at Needham Neuroscience Forum (Virtual) Transcript

Mar 15, 2023 / 02:50PM GMT

Release Date Price: $2.69 (-3.58%)

Transcript 10-K8-K

Ami Fadia

Needham & Company - Analyst

Good morning, everyone, again. This is Ami Fadia, very happy to host our next company, Athira Pharma. Thank you so much, Mark, Hans, Rachel for joining us today for the session. Just by way of a reminder to our listeners, if you have any questions that you'd like me to ask the team, feel free to send it over to me through the chat.

And with that, Mark, very glad to have you and the team here today. Thank you so much.

Mark Litton

Athira Pharma, Inc. - President & CEO

Thank you for having us.

Questions & Answers

Ami Fadia

Needham & Company - Analyst

Great. Perhaps we can start with a broader question around the CNS space. Neuroscience has been undergoing a renaissance period over the last couple of years. I wanted to know in your view, where has the most amount of progress been made, and where do you see and a need for more progress to be made from here?

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.